Noom’s core app costs a recurring subscription fee, cheapest on an annual plan and most expensive billed monthly, and it is worth it mainly for people who will actually use the daily lessons, food log, and coach messaging. It is not a good deal for someone who already tracks intake or who mainly wants medication, because the drug is billed separately on a pricier tier. The honest answer is that value depends entirely on which version you buy and how much you use it.
What are you actually paying for?
Noom sells two very different things under one brand. The first is a behavior-change app: short daily psychology lessons, a color-coded food logger, weight tracking, and access to a human coach through messaging. The second is a medical tier that layers clinician visits and, where appropriate, a prescription for a GLP-1 medication on top of the app.
Most Noom reviews blur these together, which is where confusion about the price starts. The subscription buys the software and coaching. It does not buy the medication. Anyone reading a headline monthly figure should assume that number covers the app only, and that the medical track adds visit fees and drug cost as separate lines.
How does Noom price its plans?
Noom uses the standard subscription pattern: the longer the commitment, the lower the effective monthly rate. A month-to-month plan carries the highest per-month price, while a six-month or annual plan drops it substantially. Free trials are common, and they usually convert to a full billing cycle if not canceled, so the first real charge can be larger than expected.
The behavior-only plan is the cheaper product. The medication plan is the expensive one, and its total cost is not a single number. It combines a program or membership fee, clinician oversight, and the medication itself, which may run through insurance or be paid in cash depending on coverage. Someone comparing prices needs to add all three, not just the app line.
Which route are you comparing against?
| Option | Leads with | Main limitation |
|---|---|---|
| Noom behavior app | Daily lessons, logging, coaching | No medication, value depends on use |
| Noom medication tier | Coaching plus prescribing | Drug billed separately, higher total |
| Prescribing-first telehealth | Fast access to medication | Lighter behavior support |
| Compounded medication route | Flat cash price per month | Not an FDA-approved product |
Is the behavior program worth it on its own?
For the right person, yes. Structured food logging and daily prompts do help some people build steadier eating patterns, and having a coach to message can keep a plan alive through a rough week. The psychology framing is Noom’s real differentiator, and it is a legitimate one. Behavioral support is a recognized part of obesity care rather than a gimmick, and current clinical guidance treats lifestyle intervention as the foundation that medication is added onto, as reflected in the 2025 pharmacotherapy guideline update and the AGA guideline on pharmacological interventions for obesity.
The catch is engagement. The app only works if the lessons get read and the food gets logged, and adherence to any tracking tool fades for most people within weeks. If a phone already has a free calorie tracker that goes unused, paying for a nicer one rarely changes the outcome. Buy the behavior plan if the coaching and daily structure are the specific things missing, and skip it if the honest answer is that self-tracking has never stuck before.
What does the medication tier really cost?
This is where sticker shock arrives. The medication plan pairs the app with clinician visits and prescribing, and if a GLP-1 drug is prescribed, that drug is its own expense. Brand medication carries a high list price, and what a person pays turns on coverage far more than on the program fee. The framing matters because obesity is now defined with formal diagnostic criteria, as set out in the 2025 work on the definition and diagnostic criteria of clinical obesity, and coverage decisions increasingly hinge on that documentation.
The medications themselves are worth understanding before paying for access to them. GLP-1 and dual GIP/GLP-1 receptor agonists work through appetite and metabolic pathways described in research on their mechanisms of action, with the dual-agonist class tracing back to early work on LY3298176. There is also a newer oral option: orforglipron, sold as FOUNDAYO, which was approved in 2026 for weight management and studied in trials such as the early daily oral GLP-1 receptor agonist study and later phase work summarized in its first-approval review. An oral drug may change the cost math for people who dislike injections, though it is still a prescription expense on top of any program fee.
How does it stack against other telehealth options?
Noom leads with behavior and adds medication. Prescribing-first services such as Ro, Hims and Hers, and Henry Meds do the reverse, putting fast medication access first with lighter coaching around it. LillyDirect and NovoCare are the manufacturer self-pay routes for brand drugs. None of these is universally best; the right pick depends on whether the priority is habit change or the medication itself.
There is also the compounded route, which some people choose when brand cost is out of reach. Compounded semaglutide and tirzepatide are prepared by compounding pharmacies and are not FDA-approved products, so they trade regulatory assurance for a predictable cash price. Supervised telehealth practices such as FormBlends publish flat monthly pricing for compounded options with prescribing handled by a licensed clinician, and readers weighing that path against a Noom subscription can compare the full details here before deciding. That comparison only makes sense once coverage status is known, since insurance can flip which route is cheaper.
Who should skip Noom?
Anyone whose main goal is treatment for a metabolic condition should think carefully. People with liver involvement, for instance, are managed under specific guidance like the EASL-EASD-EASO guidelines on metabolic dysfunction-associated steatotic liver disease, and a coaching app is not the right primary tool for that. Skip Noom if the real need is clinical care rather than habit support, if self-tracking has repeatedly failed, or if the budget only covers the app while the actual goal requires medication that the app does not include.
Key takeaways
- The advertised Noom price usually covers the app only, not any prescribed medication.
- Annual billing is cheapest per month; month-to-month is the priciest way to try it.
- The behavior program is worth it only if the lessons and logging get used consistently.
- The medication tier’s true cost is the program fee plus visits plus the drug, driven mostly by coverage.
See also: Oxytocin Nasal Spray: I Graded Six Sellers Against Reality, and It Was Not Close
Frequently asked questions
How much does Noom actually cost?
The core behavior program is a recurring subscription, usually cheapest when billed annually and most expensive month to month. The medication tier costs far more because it adds clinician visits and, if prescribed, the drug itself, which is billed separately from the app fee.
Does the monthly price include weight-loss medication?
No. The app subscription and any prescribed medication are separate charges. The advertised app price does not cover a GLP-1 drug, so budgeting only for the subscription understates the real monthly cost of the medication track.
Is Noom worth it without the medication?
It can be for people who want structured food logging, daily lessons, and coach messaging and who will use them consistently. For someone who already tracks intake or wants clinical treatment for obesity, the app alone is a weaker fit.
How does Noom compare to other telehealth weight programs?
Noom leads with behavior coaching and adds medication as a tier. Programs like Ro, Hims and Hers, and Henry Meds lead with prescribing. Which is better depends on whether the priority is habit change or access to medication.
Is compounded medication a cheaper Noom option?
Compounded semaglutide or tirzepatide is prepared by a compounding pharmacy and is not an FDA-approved product. It may cost less per month than brand medication, but it has not been through the approval process behind the brand trial evidence.
